U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R...(deliveredwith the Biojector(R) 2000 need...),Health

Date:11/6/2008

delivered with the Biojector(R) 2000 needle-free injection system. Preliminary results indicated that the vaccine was safe and well-tolerated at both the 1 mg low dose and 5 mg high dose tested, but even at the high dose induced only low levels of neutralizing antibody titers in less than half of the animals. Under a Collaborative Research and Development Agreement (CRADA) with Vical, the NMRC developed a tetravalent dengue vaccine containing prM and E genes for all four serotypes of dengue, and formulated with the Vaxfectin(R) adjuvant. Nonhuman primate immunogenicity and challenge data with the tetravalent DNA vaccine, formulated with or without the Vaxfectin(R) adjuvant and delivered by needle-free injection using the Biojector(R) 2000, were promising.

Four of four (100%) rhesus macaques receiving the Vaxfectin(R)-formulated vaccine developed neutralizing antibodies to all four serotypes of dengue one month after the second injection (Day 56), and were highly protected against challenge, exhibiting very limited viremia (group mean 0.75 days). Only one of four (25%) macaques receiving the unformulated vaccine developed neutralizing antibodies to all four serotypes of dengue one month after the second injection (Day 56), and were partially protected against challenge, exhibiting limited viremia (group mean 2.00 days). The unvaccinated control macaques did not develop any neutralizing antibodies, and were unprotected against challenge, exhibiting typical viremia (group mean 3.33 days). The next step in this program will be to advance this vaccine to Phase 1 human testing.

About Dengue

Dengue virus infects up to 100 million people each year. Its impact is magnified by the lack of effective antiviral drugs and vaccines. As many as half a million people develop severe dengue disease each year, causing tens of thousands of deaths, particularly where healthcare is limited.

Dengue fever can be caused by any one of four serotypes of dengue virus
'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Promising Cystic Fibrosis Compound on Track for Development
3. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
4. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
5. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
8. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
9. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
10. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
11. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies